Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vinculin is a 117-kDa cytoskeletal actin-binding protein, highly conserved and ubiquitously expressed, comprising a head domain (binding talin, α-actinin, catenins), a proline-rich linker, and a tail domain (binding actin, paxillin, PIP2). Vinculin exists in closed (inactive) and open (active) conformations, mediating its ability to connect adhesion receptors on the membrane—primarily integrins—to the dynamic actin cytoskeleton. This connection stabilizes focal adhesions and adherens junctions, influences cell shape, regulates migration, and transmits mechanical signals. Metavinculin is a cardiac isoform with additional protein sequence and disease relevance. Disruption of vinculin impacts cell adhesion, migration, and can contribute to disease such as cancer and cardiomyopathy.
Not applicable for drugs (no direct therapeutic targeting). Vinculin functions through conformational change (inactive/active states), regulated by ligand binding (e.g., talin, α-actinin, actin), and phosphorylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vinculin (VCL).